Last $67.81 USD
Change Today -0.11 / -0.16%
Volume 328.7K
CBST On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
NASDAQ GS
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

cubist pharmaceuticals inc (CBST) Snapshot

Open
$67.87
Previous Close
$67.92
Day High
$68.60
Day Low
$67.40
52 Week High
02/28/14 - $82.12
52 Week Low
07/18/13 - $51.31
Market Cap
5.1B
Average Volume 10 Days
611.5K
EPS TTM
$1.05
Shares Outstanding
75.3M
EX-Date
--
P/E TM
64.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for CUBIST PHARMACEUTICALS INC (CBST)

cubist pharmaceuticals inc (CBST) Related Businessweek News

View More BusinessWeek News

cubist pharmaceuticals inc (CBST) Details

Cubist Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of pharmaceutical products for medical needs in the acute care environment in the United States. The company offers CUBICIN (daptomycin for injection), a once-daily, bactericidal, intravenous antibiotic with activity against methicillin-resistant Staphylococcus aureus; DIFICID for the treatment of clostridium difficile-associated diarrhea (CDAD); and ENTEREG (alvimopan), an oral peripherally-acting mu opioid receptor antagonist to accelerate upper and lower gastrointestinal recovery. It also develops Tedizolid Phosphate, a novel antibiotic product candidate for the treatment of serious gram-positive bacterial infections; and Ceftolozane/tazobactam, an I.V. antibacterial product candidate for the treatment of certain serious gram-negative bacterial infections in the hospital. In addition, the company develops Surotomycin, an oral lipopeptide, which is in Phase III clinical trials to treat CDAD; and Bevenopran, an oral, peripherally-acting mu opioid receptor antagonist for the treatment of opioid-induced constipation in patients with chronic non-cancer pain. Cubist Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Lexington, Massachusetts.

873 Employees
Last Reported Date: 02/25/14
Founded in 1992

cubist pharmaceuticals inc (CBST) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $750.0K
President, Chief Operating Officer and Direct...
Total Annual Compensation: $600.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $358.7K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $475.0K
Senior Vice President and General Manager of ...
Total Annual Compensation: $440.2K
Compensation as of Fiscal Year 2013.

cubist pharmaceuticals inc (CBST) Key Developments

Cubist Pharmaceuticals Inc. Receives Approval from U.S. Food and Drug Administration for SIVEXTRO

Cubist Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) approved SIVEXTRO(TM) (tedizolid phosphate) for the treatment of adult acute bacterial skin and skin structure infections (ABSSSI). SIVEXTRO addresses ABSSSI caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), which has been categorized by the U.S. Centers for Disease Control and Prevention (CDC) as a serious public health threat. Administered once daily, SIVEXTRO offers an effective, short six-day course of therapy. SIVEXTRO is a novel oxazolidinone with in vitro activity against clinically significant susceptible Gram-positive pathogens including MRSA and is now approved in both an intravenous (I.V.) and oral formulations. The New Drug Application (NDA) for SIVEXTRO was supported by two global Phase 3 studies, which met primary and secondary endpoints defined by the FDA and the European Medicines Agency (EMA). These studies demonstrated that SIVEXTRO 200 mg administered once daily for six days was statistically non-inferior to 600 mg of linezolid taken twice a day for 10 days. In these studies, the adverse event rates were similar for patients treated with SIVEXTRO and linezolid. Gastrointestinal adverse events (diarrhea, nausea and vomiting) were the most commonly reported in both treatment groups. SIVEXTRO is one of the first medicines approved in the U.S. that the FDA designated as a Qualified Infectious Disease Product (QIDP) for its indication, ABSSSI, according to the Generating Antibiotic Incentives Now (GAIN) Act of 2012. The QIDP designation qualifies SIVEXTRO for certain incentives related to the development of new antibiotics, including a five year extension of Hatch-Waxman exclusivity.

Cubist Pharmaceuticals Inc. Announces Acceptance of Ceftolozane/Tazobactam New Drug Application by U.S. Food and Drug Administration

Cubist Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has accepted the company's New Drug Application for its investigational antibiotic ceftolozane/tazobactam with Priority Review. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of December 21, 2014. Cubist is seeking FDA approval of ceftolozane/tazobactam for the treatment of complicated urinary tract Infections and complicated intra-abdominal infections. The NDA is based on positive data from two pivotal Phase 3 clinical trials of ceftolozane/tazobactam in complicated urinary tract infections and complicated intra-abdominal infections. These studies met both the FDA and the European Medicines Agency (EMA) specified primary endpoints. Results of the secondary analyses were consistent with and supportive of the primary outcomes. In the clinical trials ceftolozane/tazobactam demonstrated activity against problematic Gram-negative bacteria, including Pseudomonas aeruginosa and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (E. coli) and Klebsiella pneumoniae in patients with complicated infections.

Cepheid and AstraZeneca, Cubist Pharmaceuticals, Inc. and GSK Partner on A Diagnostic Test to Help Tackle Multidrug-Resistant Bacterial Infections

Cepheid announced a new collaboration with AstraZeneca, Cubist Pharmaceuticals Inc. and GSK intended to promote transformational change in infectious disease therapy by developing a rapid diagnostic test that can target multi-drug resistant pathogens and support the appropriate use of antibiotics. Targeting bacterial infections with the right treatment will slow the development of resistance that has led to a crisis in treating infections. Xpert Carba-R is a rapid test under development for use with rectal swab samples to identify the presence of potentially life threatening bacteria. Specifically, the consortium is working to extend the number of body sample types from rectal swabs to other body samples such as respiratory samples from patients with pneumonia. Xpert Carba-R is commercially available outside the US, and is targeted for commercial release in the US in 2015, subject to regulatory approval.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBST:US $67.81 USD -0.11

CBST Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €10.81 EUR -0.19
Salix Pharmaceuticals Ltd $131.81 USD -2.03
Santen Pharmaceutical Co Ltd ¥5,780 JPY -10.00
Synergy Health PLC 1,384 GBp -22.00
Theravance Inc $28.93 USD -0.03
View Industry Companies
 

Industry Analysis

CBST

Industry Average

Valuation CBST Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.7x
Price/Book 3.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CUBIST PHARMACEUTICALS INC, please visit www.cubist.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.